| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/12/2005 | US6916487 Antiemetic, dermal penetration enhancer of a safe skin-tolerant sunscreen ester and volatile liquids |
| 07/12/2005 | US6916486 Mixture of analgesic hormones, skin penetration and sunscreen agents |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | US6916484 Sugars and sugar alcohols as isotonizing agents and has < 10 ppb of iron |
| 07/12/2005 | US6916478 Prevention, therapy infectious diseases; insertion of nucleic acids into target cells |
| 07/12/2005 | US6916476 Keyhole limpet hemocyanin (klh); anticancer agents; treating melanoma |
| 07/12/2005 | US6916471 Amplification of nitroso compouds in erythrocytes; obtain mammal, inject with therapeutic agent, monitor concentration levels of preferential nitroso compounds |
| 07/12/2005 | US6916303 Photoreduction method for hemoglobin-vesicle |
| 07/12/2005 | CA2452172A1 Methods and compositions for modulating cell activation and uses thereof |
| 07/12/2005 | CA2283518C Diagnostic agents for pancreatic exocrine function |
| 07/12/2005 | CA2245617C Ophthalmic solutions viscosified with tamarind seed polysaccharide |
| 07/12/2005 | CA2238931C Association of a retinoid with a polyamine polymer |
| 07/12/2005 | CA2230947C Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| 07/12/2005 | CA2172974C Poly-amino acidic oligonucleotide-carrier |
| 07/12/2005 | CA2165190C Dispenser containing hydrophobic agent |
| 07/07/2005 | WO2005061724A1 Self-assembling nanoparticle conjugates |
| 07/07/2005 | WO2005061701A1 Process for producing polymer composite of protein |
| 07/07/2005 | WO2005061552A1 Amphiphilic heparin derivative formed by coupling a heparin with a bile acid |
| 07/07/2005 | WO2005061548A1 Polypeptides for modulating binding of trp channel proteins and trp-associated proteins. |
| 07/07/2005 | WO2005061018A1 Matrix comprising naturally-occurring protein backbone |
| 07/07/2005 | WO2005061017A2 Electrically conductive adhesive hydrogels with solubilizer |
| 07/07/2005 | WO2005061006A1 Prodrug of anticholinergic agent |
| 07/07/2005 | WO2005061005A2 Branched polyethylene glycol for linking polymer residues to antibodies |
| 07/07/2005 | WO2005061004A1 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof |
| 07/07/2005 | WO2005061003A1 Anti-infective medical device |
| 07/07/2005 | WO2005060989A1 A pharmaceutical composition comprising an active principle and sulphobetaine |
| 07/07/2005 | WO2005060945A2 Intranasal compositions comprising zolpidem |
| 07/07/2005 | WO2005060939A2 Controlled-release pharmaceutical formulation |
| 07/07/2005 | WO2005060936A1 Cefdinir oral suspension |
| 07/07/2005 | WO2005060934A1 A novel cationic lipopolymer as a biocompatible gene delivery agent |
| 07/07/2005 | WO2005060933A1 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 07/07/2005 | WO2005060871A1 Pharmaceutical formulations of camptothecins and process for making same |
| 07/07/2005 | WO2005060375A2 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein |
| 07/07/2005 | WO2005060361A2 Pharmaceutical formulations for itraconazole |
| 07/07/2005 | WO2005051870A3 Hydrazides and derivatives production process from hydrazines and dicarboxylic acids |
| 07/07/2005 | WO2005049078A3 Immunoglobulin preparations having increased stability |
| 07/07/2005 | WO2005046637A3 Pharmaceutical formulations employing short-chain sphingolipids and their use |
| 07/07/2005 | WO2005039495A3 Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies |
| 07/07/2005 | WO2005030253A3 Photocleavable dna transfer agent |
| 07/07/2005 | WO2005018582A3 Compositions containing topical active agents and pentylene glycol |
| 07/07/2005 | WO2004091500A3 Delivery of immune response modifier compounds |
| 07/07/2005 | WO2004050849A8 Recombinant immunotoxin and use in treating tumors |
| 07/07/2005 | WO2004035629A9 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 07/07/2005 | WO2004017914A8 Inhalation composition |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | US20050148767 Self-cross-linked alkyl cellulose |
| 07/07/2005 | US20050148763 Peg-binding pth or peg-binding pth derivative |
| 07/07/2005 | US20050148753 comprising polytetrahydrofuran, hexamethylene diisocyanate and/or isophorone diisocyanate, and trimethylolpropane or dimethylolpropanoic acid; cosmetic and/or pharmaceutical preparations |
| 07/07/2005 | US20050148597 Controlled release of sterile freeze dried aripirazole in water for intramuscular injection |
| 07/07/2005 | US20050148594 Salt with choline, ethanolamine, diethanolamine, piperazine, calcium or tromethamine, optionally embedded in an enteric binder; recrystallization prevention; improved bioavailability and photostability |
| 07/07/2005 | US20050148582 N-[1-butyl-4-piperidinylmethyl[3,4-dihydro-2 oxazino[3,2-a indole-10 carboxamide as drugs with Cahpo4 or Ca3/po4/2 fillers or binders for use in treatment of irritable bowel syndrome, urinry incontience or arrhythmias |
| 07/07/2005 | US20050148569 Targeted oxidative therapeutic formulation |
| 07/07/2005 | US20050148568 Treating sarcocystis protozoa infected horses; peroxidic species from oxidation of such as geraniol, penetrating solvent;, metal chelated dye and aromatic redox compound; activating with ionizing radiation |
| 07/07/2005 | US20050148564 Gonane ring substituted with hydroxy group and alkylamide derivatives used for achieving sustained systemic concentrations of therapeutic or prophylactic GABA(gamma-aminobutyric acid)analogs following administration to animals |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148534 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 07/07/2005 | US20050148503 Comprises erythropoietin as active ingredient; for treatment of anemia, trypanosomiasis, or malaria |
| 07/07/2005 | US20050148497 Method for administering glp-1 molecules |
| 07/07/2005 | US20050147724 Use of multi-layer pigments in the food and pharmaceutical industry |
| 07/07/2005 | US20050147684 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147683 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147682 A hematopoietic growth factor, a liquid vehicle, a first and second biocompatible polymers; exhibits reverse-thermal viscosity behavior due to interaction between the first polymer and vehicle; the second polymer forms a protective colloid; sustained delivery; increased half-life; side effect reduction |
| 07/07/2005 | US20050147681 Multi-arm block copolymers as drug delivery vehicles |
| 07/07/2005 | US20050147680 Injectable veterinary composition for small animals |
| 07/07/2005 | US20050147676 Release sustaining composition and sustained release preparation |
| 07/07/2005 | US20050147674 A tablet or capsule prepared from a mixture of crystalline escitalopram oxalate having a median particle size of > 40 mu m and excipients; large particle size for use in direct compression; controlled crystallization from solution to avoid granulation and drying steps; binder-and lactose-free |
| 07/07/2005 | US20050147671 A fast-release dosage of diclofenac or diclofenzc salts in the form of a packet of powder for dissolving or suspending in water or a high-speed release layer in a bilayered tablet that comprises a fast and a slow layer; palatable and free from aftertaste and side effects; consistancy; uniformity |
| 07/07/2005 | US20050147664 Comprising one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof; active agents preferably have a particle size of about 2 microns or less; for targeting delivery of the active agents to a desired site |
| 07/07/2005 | US20050147661 Gelatin derivatives and high-molecular micelle comprising the derivatives |
| 07/07/2005 | US20050147660 Peptide-carrying bodies for immune response |
| 07/07/2005 | US20050147659 Oil/water/oil double microemulsion incorporated into solid support constituted by microporous inorganic substance or by an adsorbent colloidal inorganic substance or cross-linked swellable in water polymer, wherein drug is dissolved or dispersed in one or more phases of microemulsion; improved solubility |
| 07/07/2005 | US20050147629 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 07/07/2005 | US20050147624 Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue |
| 07/07/2005 | US20050147618 comprising blood coagulation factors and segments of an immunoglobulin fragments, used for treating hemostatic disorders |
| 07/07/2005 | US20050147617 conjugates of methoxylpolyethylene glycol-glutamic acid oligopeptide and drug such as antitumor agents, having low toxicity, improved solubility, sustain and/or control release profiles |
| 07/07/2005 | US20050147603 Employing nonimmunogenic blood products from patients with autoimmune disease |
| 07/07/2005 | US20050147598 Combining with animal fat, vegetable oil and/or polyol; oxidation resistance; shelf life |
| 07/07/2005 | US20050147592 Correcting underlying genetic defect; delivering heterologous gene encoding metabolic protein causing transduction of cells resulting in expression from transformed cell genetics |
| 07/07/2005 | US20050147587 Protein fusion comprising colony stimulating factor activity for use as tool in rapid stimulation and production of white blood cells and neutrophils |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147581 Molar ratio of acidic polymer to protein therapeutic in excess of stoichiometric requirement; such as pulmonary delivery of somatropin |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | US20050147565 using inhalants containing aerosol suspensions comprising mometasone furoate, formoterol fumarate and 1,1,1,2,3,3,3,-heptafluoropropane |
| 07/07/2005 | US20050147555 polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor |
| 07/07/2005 | DE10358387A1 Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung Powder containing low molecular weight dextran, and processes for their preparation |
| 07/07/2005 | CA2551190A1 Polypeptides for modulating binding of trp channel proteins and trp-associated proteins. |
| 07/07/2005 | CA2549966A1 Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle |
| 07/07/2005 | CA2548408A1 Cefdinir oral suspension |
| 07/07/2005 | CA2545947A1 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 07/07/2005 | CA2545805A1 Branched molecular scaffolds for linking polymer residues to biologically active moieties |
| 07/07/2005 | CA2545632A1 A pharmaceutical composition comprising an active principle and a non-detergent sulphobetaine |
| 07/07/2005 | CA2539169A1 A novel cationic lipopolymer as a biocompatible gene delivery agent |
| 07/07/2005 | CA2522421A1 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like protein |
| 07/06/2005 | EP1550719A1 Methods and medicament for inhibition the expression of a defined gene |
| 07/06/2005 | EP1550705A1 Allergen inactivator |
| 07/06/2005 | EP1550680A1 Biodegradable copolymer, and polymeric micelle composition containing the same |
| 07/06/2005 | EP1550675A1 Phospholipid derivative |
| 07/06/2005 | EP1550670A1 Fine spherical particles with satisfactory molecular orientation, spherical microcapsules comprising the same, and processes for producing these |
| 07/06/2005 | EP1550651A1 Glycerol derivative |